Lung Cancer Trials
Select Clinical Trial
Protocol Number: BA3011-002
Protocol Title: A Phase2 Study of BA3011 Alone and in Combination with Nivolumab in Adult Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) who had prior disease progression on a PD-1/L-1 inhibitor.
Eligibility: Men or women, ages 18 or older, diagnosed with metastatic non-small cell lung cancer, stage IV disease.
Contact Information: (910) 715-2200
_________________________________________________________________________________________
Protocol Number: Merck MS201923_0050
Protocol Title: A Phase II, open-label, single-arm study of Berzosertib (M6620) in combination with Topotecan in participants with relapsed platinum-resistant small-cell lung cancer.
Eligibility: Men or women, ages 18 and older, diagnosed with limited or extensive stage small cell lung cancer with confirmed progression within 90 days from completion of first-line or chemoradiation platinum-based treatment (carboplatin or cisplatin).
Contact Information: (910) 715-2200
____________________________________________________________________________________________
Protocol Number: FDI-213
Protocol Title: A Prospective Collection of Peripheral Blood from Adults for CYFRA 21-1, SCC and NSE Assay Reference Range Determination.
Eligibility: Men or women, ages 22 and older, healthy individuals, individuals currently diagnosed with certain benign diseases, individuals newly diagnosed with NSCLC and SCLC lung cancer prior to treatment, and individuals diagnosed with certain cancers at any stage and any treatment timepoint.
Contact Information: (910) 715-2200
____________________________________________________________________________________________
Protocol Number: ALCHEMIST
Protocol Title: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial
Eligibility: Men or women, ages 18 or older, diagnosed with Stage IIIA, II or large IB non-small cell lung cancer (NSCLC).
Contact Information: (910) 715-2200
____________________________________________________________________________________________
Protocol Number: MS200647_0005
Protocol Title: A multicenter, double blind, randomized, controlled study of M7824 with concurrent chemoradiation followed by M7824 versus concurrent chemoradiation plus placebo followed by Durvalumab
Eligibility: Men or women, ages 18 and older, diagnosed with non-small cell lung cancer, stage III locally advanced, unresectable disease.
Contact Information: (910) 715-2200
____________________________________________________________________________________________
Protocol Number: LUNGMAP
Protocol Title: Master Protocol to evaluate biomarker-driven therapies and immunotherapies in previously-treated non-small cell lung cancer (Lung-MAP Screening Study)
Eligibility: Men or women, ages 18 and older, diagnosed with non-small cell lung cancer, DISEASE MUST BE EITHER ADVANCED, stage IIIB or IV or recurrent.
Contact Information: (910) 715-2200
____________________________________________________________________________________________
Protocol Number: NRG-LU005
Protocol Title: LIMITED STAGE SMALL CELL LUNG CANCER (LS-SCLC): A PHASE II/III RANDOMIZED STUDY OF CHEMORADIATION VERSUS CHEMORADIATION PLUS ATEZOLIZUMAB
Eligibility: Men or women, ages 18 and older, diagnosed with limited stage small cell lung cancer.
Contact Information: (910) 715-2200
____________________________________________________________________________________________
Protocol Number: FDI 209
Protocol Title: A Prospective Longitudinal Collection of Peripheral Blood to Support the Validation of Biomarkers as an Aid in Monitoring Disease in Patients with all Stages of Lung Cancer
Eligibility: Men and women age 18 and older, diagnosed with Lung Cancer.
Contact Information: (910) 715-2200
____________________________________________________________________________________________
Protocol Number: SWOG 1914; NCT04214262
Protocol Title: A Randomized Phase III Trial of Induction/ Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage Non-Small Cell Lung Cancer
Eligibility: Men and women age 18 and older, diagnosed with Early Stage Non-Small Cell Lung Cancer that are not candidates for surgical resection.
Contact Information: (910) 715-2200
____________________________________________________________________________________________
Protocol Number: SWOG 1929; NCT04334941
Protocol Title: Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Eligibility: Men and women age 18 and older, diagnosed with Extensive Stage Small Cell lung cancer.
Contact Information: (910) 715-2200